What do medicinal chemists actually make? A 50-year retrospective.

[1]  A. Ghose,et al.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.

[2]  S. Bembenek,et al.  Ligand binding efficiency: trends, physical basis, and implications. , 2008, Journal of medicinal chemistry.

[3]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[4]  Anda Vintiloiu,et al.  Organogels and their use in drug delivery--a review. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[5]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[6]  D. E. Clark,et al.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.

[7]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[8]  L. Lai,et al.  Calculating partition coefficient by atom-additive method , 2000 .

[9]  Michael J. Keiser,et al.  Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors† , 2010, Journal of medicinal chemistry.

[10]  T. Keller,et al.  A practical view of 'druggability'. , 2006, Current opinion in chemical biology.

[11]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[12]  Andreas Bender,et al.  Databases: Compound bioactivities go public , 2010 .

[13]  Li Xing,et al.  Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.

[14]  K. Tai,et al.  The selectivity of K+ ion channels: testing the hypotheses. , 2008, Biophysical journal.

[15]  M. Waring.  Lipophilicity in drug discovery , 2010, Expert Opinion on Drug Discovery.

[16]  J. Gasteiger,et al.  Prediction of Aqueous Solubility of Organic Compounds by Topological Descriptors , 2003 .

[17]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[18]  Alastair J J Wood,et al.  A proposal for radical changes in the drug-approval process. , 2006, The New England journal of medicine.

[19]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[20]  Brett A Tounge,et al.  Ligand efficiency and fragment-based drug discovery. , 2009, Drug discovery today.

[21]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[22]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[23]  A. C. Rigby,et al.  The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow. , 2009, Drug discovery today.

[24]  Patrick Soon-Shiong,et al.  Protein nanoparticles as drug carriers in clinical medicine. , 2008, Advanced drug delivery reviews.

[25]  Big pharma slims down to bolster productivity , 2007, Nature Reviews Drug Discovery.

[26]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.

[27]  J. Proudfoot,et al.  The evolution of synthetic oral drug properties. , 2005, Bioorganic & medicinal chemistry letters.

[28]  Stephen R. Johnson,et al.  Trends in kinase selectivity: insights for target class-focused library screening. , 2011, Journal of medicinal chemistry.

[29]  F. Koehn,et al.  The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.

[30]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[31]  Nigel Greene,et al.  Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. , 2010, Bioorganic & medicinal chemistry letters.

[32]  E. Negishi,et al.  Highly general stereo-, regio-, and chemo-selective synthesis of terminal and internal conjugated enynes by the Pd-catalysed reaction of alkynylzinc reagents with alkenyl halides , 1977 .

[33]  S. Carney.  How can we avoid the productivity gap? , 2005, Drug discovery today.

[34]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[35]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[36]  John S. Delaney,et al.  ESOL: Estimating Aqueous Solubility Directly from Molecular Structure , 2004, J. Chem. Inf. Model..

[37]  P. Hoffmann,et al.  Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. , 2006, Journal of pharmacological and toxicological methods.

[38]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[39]  Xian Jun Loh,et al.  Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. , 2008, Advanced drug delivery reviews.

[40]  T. Ritchie,et al.  The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.

[41]  Bruce L. Booth,et al.  Opinion: Prospects for productivity , 2004, Nature Reviews Drug Discovery.

[42]  J. Vederas,et al.  Drug Discovery and Natural Products: End of an Era or an Endless Frontier? , 2009, Science.

[43]  Pedro Cuatrecasas,et al.  Drug discovery in jeopardy. , 2006, The Journal of clinical investigation.

[44]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property-Based Rules? , 2007, J. Chem. Inf. Model..

[45]  Luhua Lai,et al.  A New Atom-Additive Method for Calculating Partition Coefficients , 1997, J. Chem. Inf. Comput. Sci..

[46]  Jayaraman Chandrasekhar,et al.  Strategies and tactics for optimizing the Hit-to-Lead process and beyond--a computational chemistry perspective. , 2008, Drug discovery today.

[47]  Jochem Alsenz,et al.  Miniaturized Assay for Solubility and Residual Solid Screening (SORESOS) in Early Drug Development , 2007, Pharmaceutical Research.

[48]  Paul D Leeson,et al.  Time-related differences in the physical property profiles of oral drugs. , 2004, Journal of medicinal chemistry.

[49]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[50]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[51]  J. Castell,et al.  Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry. , 2008, Current drug metabolism.

[52]  S. Hitchcock,et al.  Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.

[53]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[54]  D. E. Clark.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.

[55]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[56]  Stephen R. Johnson,et al.  The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy) , 2008, J. Chem. Inf. Model..

[57]  Wendy A. Warr,et al.  ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI) , 2009, J. Comput. Aided Mol. Des..

[58]  Kristina Luthman,et al.  Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans , 1997, Pharmaceutical Research.

[59]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.

[60]  W Patrick Walters,et al.  Prediction of 'drug-likeness'. , 2002, Advanced drug delivery reviews.

[61]  R. Heck,et al.  Palladium-catalyzed vinylic hydrogen substitution reactions with aryl, benzyl, and styryl halides , 1972 .

[62]  Tudor I. Oprea,et al.  Property distribution of drug-related chemical databases* , 2000, J. Comput. Aided Mol. Des..

[63]  Arthur M. Doweyko,et al.  QSAR: dead or alive? , 2008, J. Comput. Aided Mol. Des..

[64]  Y. Martin,et al.  A practitioner's perspective of the role of quantitative structure-activity analysis in medicinal chemistry. , 1981, Journal of medicinal chemistry.

[65]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[66]  Z. Rankovic,et al.  Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.

[67]  A. Aronov.  Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. , 2006, Journal of medicinal chemistry.

[68]  Norio Miyaura,et al.  A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides , 1980 .

[69]  Peter Ertl,et al.  The graphical representation of ADME-related molecule properties for medicinal chemists. , 2011, Drug discovery today.

[70]  Samuel H. Yalkowsky,et al.  Prediction of Drug Solubility by the General Solubility Equation (GSE) , 2001, J. Chem. Inf. Comput. Sci..

[71]  P. Zarrinkar,et al.  High-throughput kinase profiling as a platform for drug discovery , 2008, Nature Reviews Drug Discovery.

[72]  A. Stammati,et al.  The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics , 2005, Cell Biology and Toxicology.

[73]  J J Baldwin,et al.  Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.

[74]  James G. Nourse,et al.  Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..

[75]  Samuel H. Yalkowsky,et al.  Relationships between aqueous solubility and octanol-water partition coefficients , 1980 .

[76]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[77]  Terry Kenakin.  Functional selectivity in GPCR modulator screening. , 2008, Combinatorial chemistry & high throughput screening.

[78]  Paul D. Leeson,et al.  Impact of ion class and time on oral drug molecular properties , 2011 .

[79]  H. van de Waterbeemd,et al.  Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.

[80]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[81]  Peter Ertl,et al.  Relationships between Molecular Complexity, Biological Activity, and Structural Diversity , 2006, J. Chem. Inf. Model..

[82]  C. Schneider,et al.  Typical pitfalls in applications for marketing authorization of biotechnological products in Europe , 2008, Nature reviews. Drug discovery.

[83]  Ajay,et al.  Designing libraries with CNS activity. , 1999, Journal of medicinal chemistry.

[84]  Dimitris K. Agrafiotis,et al.  Enhanced SAR Maps: Expanding the Data Rendering Capabilities of a Popular Medicinal Chemistry Tool , 2009, J. Chem. Inf. Model..